BCG‑HealthCoise Report Highlights India’s Emerging Life‑Science Ecosystem

Key drivers identified in the study are a government commitment of about $5 billion for early‑stage and translational research, stronger collaboration between academia and industry, regulatory reforms that have trimmed drug‑development timelines from 180‑270 days to 60‑120 days, and shared facilities such as Genome Valley and C‑Camp. Private‑equity and venture‑capital inflows into the pharma sector have more than doubled, reaching $731 million in FY 2026.